Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial
Authors' conclusion
Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c. Benefits were consistent across BMI and HbA1c categories, supporting effectiveness beyond weight or glycemic changes.
Study context
- Population
- People with symptomatic peripheral artery disease (PAD) and T2D; median diabetes duration 12.2 years, HbA1c 7.1%, BMI 28.7 kg/m²; 35.1% used SGLT2i, 31.7% insulin
- Participants
- 792 people
- Comparison
- Once-weekly SC semaglutide 1.0 mg vs placebo, by baseline T2D characteristics
- Primary endpoint
- Ratio to baseline (ETR) in maximum walking distance (MWD), constant load treadmill
- Follow-up
- 52 weeks
Methodological detailsrandomized, placebo-controlled, double-blind, subgroup analyses, Mixed model for repeated measurements with treatment-by-subgroup interaction
- Randomized
- Placebo-controlled
- Double-blind
- Subgroup analyses
- Mixed model for repeated measurements with treatment-by-subgroup interaction
Primary result
As reported in the abstract
MWD (ETR) by subgroup
Diabetes duration <10 vs ≥10 years: ETR
1.15 vs. 1.13
P = 0.80
BMI <30 vs ≥30 kg/m²: ETR
1.12 vs. 1.16
P = 0.58
HbA1c <7% and ≥7%: ETR
1.13
P = 0.99
Secondary outcomes
Pain-free walking distance (PFWD) across subgroups · 52 weeks
- Semaglutide improved PFWD across subgroups
- P > 0.1 for all interactions
BMI reduction and maximum walking distance (MWD)
- BMI reduction correlated weakly with MWD improvements and was more pronounced in control individuals with higher baseline BMI
Safety
- Safety outcomes consistent across subgroups
Original publication
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. Published 21 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →